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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.08.037Objective: We reviewed our experience with preoperative chemoradiotherapy in
patients with adenocarcinoma of the distal esophagus and pretreatment endoscopic
ultrasonography-identified celiac adenopathy.
Methods: One hundred eighty-six patients with adenocarcinoma of the distal esoph-
agus were staged with endoscopic ultrasonography before treatment from 1997
through 2004. All patients were treated with concurrent chemoradiotherapy (CRT
group) and surgical intervention or induction chemotherapy followed by concurrent
chemoradiotherapy (C¡CRT group) and surgical intervention. Survival analysis
(excluding operative mortality) evaluated various pretreatment factors.
Results: Multivariable Cox regression analysis showed that pretreatment endoscopic
ultrasonography-identified celiac adenopathy was a significant predictor of de-
creased long-term survival (P  .03). Median and 3-year survivals were 49 months
and 54% in the endoscopic ultrasonography-identified cN0 M0 group (n  65), 45
months and 56% in the endoscopic ultrasonography-identified cN1 M0 group (n 
96), and 19 months and 12% in the endoscopic ultrasonography-identified celiac
adenopathy (cM1a) group (n 18; P  .03). Increased systemic relapse was noted in
the endoscopic ultrasonography-identified cM1a group (44% vs 22%, P  .07). The
only factor associated with increased survival in the endoscopic ultrasonography-
identified cM1a group (27 vs 15 months, P  .02) was the addition of induction
chemotherapy before concurrent chemoradiotherapy and surgical intervention.
Conclusions: Endoscopic ultrasonography-identified celiac adenopathy in patients
with adenocarcinoma of the distal esophagus conveys a poor prognosis despite
preoperative chemoradiotherapy. These patients should be stratified in future mul-
timodality trials. The investigation of induction chemotherapy before concurrent
chemoradiotherapy might be warranted in this high-risk group of patients.
Distal esophageal adenocarcinoma associated with celiac lymph node metas-tasis has been associated with a high risk of recurrence and poor overallsurvival after esophagectomy.1 Clinical staging with the use of endoscopic
ultrasonography (EUS) has permitted the identification of patients with celiac
adenopathy before the initiation of treatment with an accuracy of 90% (and up to
100% when fine-needle aspiration is added).2 Efforts to identify this cohort of
patients by means of noninvasive testing has resulted in reports associating EUS-
identified celiac adenopathy (cM1a) with poor survival in patients treated with
surgical intervention alone,3 suggesting that patients with EUS-identified celiac
adenopathy could be candidates for further treatment. Although no clear treatment
strategy has emerged for patients with EUS-identified celiac adenopathy, the use of
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eral centers to treat patients with locally advanced esopha-
geal cancer.4,5 We therefore evaluated our experience with
preoperative chemoradiotherapy in patients with adenocar-
cinoma of the distal esophagus and EUS-identified celiac
adenopathy at initial presentation.
Patients and Methods
Patients
From a prospectively maintained database at the University of
Texas M.D. Anderson Cancer Center, 544 patients were identified
who were treated with surgical intervention from January 1997
through March 2004. Of these patients, 241 were excluded because
they did not receive pretreatment EUS at our institution, 50 were
excluded because they did not have adenocarcinoma of the distal
esophagus, 3 were excluded because of known distant metastasis,
49 were excluded because they did not undergo preoperative
chemoradiotherapy, and 15 were excluded because they did not
undergo primary esophagectomy (redo esophagectomy, salvage
esophagectomy, or exploration). The final cohort was 186 patients
with primary adenocarcinoma of the distal esophagus, defined as
distal to the inferior pulmonary vein up to and including the
gastroesophageal junction, who underwent pretreatment EUS and
received preoperative chemoradiotherapy followed by primary
esophagectomy. Informed consent was obtained, and the study was
performed with approval from the M.D. Anderson Cancer Center
Review Board. Pretreatment EUS stratified these patients into 3
groups: the node-negative group (cN0 M0, n  71), the regional
adenopathy group (cN1 M0, n  97), and the celiac adenopathy
group (cM1a, n  18).
Preoperative Assessment
All patients were confirmed to have adenocarcinoma of the distal
esophagus with esophagoscopy and biopsy. EUS and computed
tomography of the chest and abdomen were performed to deter-
mine pretreatment clinical stage. Pretreatment positron emission
tomography was performed in 83 (45%) patients. Lymph nodes
identified by means of EUS were characterized by the following
criteria: round shape, hypoechoic texture and sharp margin, or size
greater than 10 mm. Any lymph node found within 1 cm of the
celiac axis manifesting any one or more of the above criteria was
considered to have metastatic involvement. Patients were assessed
by a multidisciplinary team (thoracic surgeon, medical oncologist,
radiation oncologist, gastroenterologist, and radiologist) to deter-
mine tumor resectability and physiologic ability to tolerate preop-
erative chemoradiotherapy and surgical intervention.
Preoperative Chemoradiotherapy
All patients received neoadjuvant therapy and were treated on
Abbreviations and Acronyms
cM1a celiac adenopathy
EUS  endoscopic ultrasonographyinstitutional protocols with induction chemotherapy followed by
66 The Journal of Thoracic and Cardiovascular Surgery ● Januaconcurrent chemoradiotherapy or off protocol with concurrent
chemoradiotherapy alone. Patients treated on institutional proto-
cols received up to 2 cycles of irinotecan (45 mg/m2), docetaxel
(Taxotere; 33 mg/m2), and 5-fluorouracil (2 g/m2 as a 24-hour
infusion). This was followed by concurrent chemoradiotherapy
(50.4 Gy in 28 fractions) and irinotecan (30 mg · m2 · wk1 for
5 weeks), docetaxel (20 mg · m2 · wk1 for 5 weeks), and
5-fluorouracil (300 mg · m2 · d1). Patients treated off protocol
received concurrent radiotherapy (50.4 Gy in 28 fractions) and
chemotherapy, consisting of either cisplatin and 5-fluorouracil or
paclitaxel and carboplatin.
Surgical Intervention
Operative resection was performed approximately 4 to 6 weeks
after completion of the preoperative regimen. Four operative ap-
proaches were used. The Ivor Lewis esophagectomy used a right
thoracotomy and laparotomy for subtotal esophagectomy and
proximal gastrectomy with a mediastinal and abdominal lymph-
adenectomy. The McKeown transthoracic esophagectomy in-
volved resection of the entire thoracic esophagus with mediastinal
and abdominal lymphadenectomy, followed by a cervical anasto-
mosis. The transhiatal resection involved a subtotal esophagec-
tomy with abdominal and lower thoracic lymphadenectomy
through an abdominal incision, followed by a cervical anastomosis
with the conduit in the posterior mediastinal position. The mini-
mally invasive esophagectomy involved thoracoscopic and lapa-
roscopic mobilization of the esophagus and stomach, followed by
an open cervical anastomosis. Lymph node dissections were per-
formed in similar fashion to open procedures in abdominal and
thoracic compartments. Thoracic lymphadenectomy included level
7 (subcarinal), level 8 (periesophageal), and level 9 (inferior pul-
monary ligament) nodes. Abdominal lymphadenectomy included
level 16 (perigastric), level 17 (left gastric), and level 18 (hepatic
artery) nodes. Level 20 (celiac) nodes were taken separate from the
specimen when they were found to be suspicious for malignant
involvement. All patients received a tube jejunostomy for tempo-
rary enteral nutrition.
Follow-up
Patients were assessed at 1, 3, 6, and 12 months and then every 6
months thereafter. Median potential follow-up was 32 months
(range, 1-87 months) in the cN0 M0 group, 34 months (range, 1-86
months) in the cN1 M0 group, and 30 months (range, 1-77 months)
in the cM1a group.
Statistical Analysis
Patient characteristics were compared by using analysis of vari-
ance, the Pearson 2 test, or the Fisher exact test where appropri-
ate. Survival distributions were graphically displayed by using the
Kaplan-Meier method. Differences in survival distributions were
assessed by using the log-rank test. Overall survival was calculated
from the date of surgical intervention to the date of death or the
date of last follow-up. Disease-free survival was similarly calcu-
lated from the date of surgical intervention to the date of disease
recurrence or death. Analysis of survival excluded operative mor-
tality defined as death within 30 days after the operation or death
during the same hospitalization. Univariable Cox regression anal-
ysis, including only preoperative patient factors, was performed to
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regression model was then performed. A stepwise variable selec-
tion procedure was used to identify variables most associated with
survival in a multivariable context (P  .10). Data analysis was
performed by our departmental biostatistician (A.M.C.) using the
Statistical Package for Social Sciences (SPSS version 11.5.2.1;
SPSS Inc, Chicago, Ill).
Results
Demographics and Preoperative Characteristics
All of the patients included in this analysis underwent
preoperative chemoradiotherapy and surgical resection and
were identified as having adenocarcinoma of the distal
esophagus. Pretreatment EUS stratified patients according
to nodal involvement into 3 groups: the node-negative
group (cN0 M0, n  71), the regional adenopathy group
(cN1 M0, n  97), and the celiac adenopathy group (cM1a,
n  18). The groups did not differ with respect to age, sex,
tumor stage, histologic grade, or the presence of Barrett’s
mucosa (Table 1).
There was a significant difference in tumor size, as
determined by pretreatment esophagogastroduodenoscopy,
ranging from 4.1 cm in the node-negative group to 6.0 cm
in the celiac adenopathy group (P  .004, Table 1). Higher
tumor stage and worse tumor differentiation were observed
in the more advanced groups, but these differences were not
statistically significant. The preoperative chemoradiother-
apy regimen was similar between groups, with 69 (37%)
patients receiving concurrent chemoradiotherapy and 117
(63%) patients receiving induction chemotherapy followed
TABLE 1. Pretreatment characteristics according to EUS-i
EUS-identified node status cN0 M0 (n  71)
Age, y (median [range]) 57 (23-76)
Sex
Male 65 (92%)
Female 6 (8%)
Tumor stage
cT1 0 (0%)
cT2 16 (23%)
cT3 54 (76%)
cT4 1 (1%)
Tumor size, cm (mean  SD) 4.1  1.7
Histologic grade
Well 4 (6%)
Moderately 36 (51%)
Poor 23 (32%)
Unspecified 8 (11%)
Barrett’s mucosa 27 (38%)
Preoperative therapy
C/RT 26 (37%)
C¡C/RT 45 (63%)
EUS, Endoscopic ultrasonography; SD, standard deviation; C/RT, concurren
chemoradiotherapy. *P value calculated from mean ages.by concurrent chemoradiotherapy.
The Journal of ThoracPostoperative Characteristics
Ivor Lewis esophagectomy with lymph node dissection was
the most common operative approach in this study (Table
2). The decision to use the transhiatal or McKeown ap-
proach was operator dependent. Operative mortality was not
different between patients with cN0 M0, cN1 M0, or cM1a
disease (overall 2.7%, P  .22). The rate of pathologic
complete response after preoperative chemoradiotherapy
was similar among all 3 lymph node groups (overall 26%,
P  .65). Pathologically confirmed metastasis to the celiac
nodes (pM1a) was confirmed in 5 (28%) of 18 patients in
the EUS-identified cM1a group after chemoradiotherapy
and surgical resection.
We explored the patterns of failure for the individual
groups and found that the cM1a group demonstrated a
greater rate of distant recurrence (8/18 [44%]) compared
with the cN0 M0 (13/71 [18%]) and cN1 M0 (25/97 [26%],
P  .07) groups. Both overall survival (Figure 1) and
disease-free survival were significantly less in the cM1a
group (median overall survival, 19 months) when compared
with those of the cM0 groups (cN0 M0 and cN1 M0
combined: median overall survival, 46 months; P  .03).
Factors Associated With Survival in Patients With
Adenocarcinoma of the Distal Esophagus
Univariable Cox regression demonstrated that only the pres-
ence of EUS-identified celiac adenopathy (cM1a disease)
and patient performance status (American Society of Anes-
thesiologists class) were associated with patient survival
ified node status
cN1 M0 (n  97) cM1a (n  18) P value
61 (38-79) 62 (41-77) .22*
92 (95%) 17 (94%) .75
5 (5%) 1 (6%)
1 (1%) 0 (0%) .07
7 (7%) 2 (11%)
85 (88%) 16 (89%)
4 (4%) 5 (3%)
5.2  2.7 6.0 2.9 .004
3 (3%) 0 (0%) .052
33 (34%) 7 (39%)
53 (55%) 11 (61%)
8 (8%) 0 (0%)
37 (38%) 7 (39%) .99
34 (35%) 9 (50%) .48
63 (65%) 9 (50%)
oradiotherapy; C¡C/RT, induction chemotherapy followed by concurrentdent
t chem(Table 3). Neither the EUS-predicted depth of tumor inva-
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adenopathy (cN stage) was associated with survival. In
addition, the surgical approach was not associated with
survival. Stepwise multivariate Cox regression again dem-
onstrated that the presence of EUS-identified celiac adenop-
TABLE 2. Postoperative characteristics according to EUS-
EUS-identified node status cN0 M0 (n  71)
Type of operation
Ivor Lewis 45 (63%)
Transhiatal 15 (21%)
McKeown 9 (13%)
Minimally invasive 2 (3%)
Operative mortality 4 (6%)
pCR 20 (28%)
pT
pT0 21 (30%)
pT1 10 (14%)
pT2 11 (15%)
pT3 29 (41%)
pT4 0 (0%)
pN 22 (31%)
pM1a 1 (1%)
Locoregional recurrence 7 (10%)
Distant recurrence 13 (18%)
Disease-free survival†
Median (mo) 46
3-y 56%
Overall survival†
Median (mo) 49
3-y 54%
EUS, Endoscopic ultrasonography. *P values are calculated from the cM0 g
was 32 months. Operative mortality was excluded.
Figure 1. Overall survival of patients with adenocarcinoma of the
distal esophagus according to pretreatment and EUS-identified
node status (cM1a vs cN0 M0 and cN1 M0, P  .03).
68 The Journal of Thoracic and Cardiovascular Surgery ● Januaathy and performance status were independently associated
with survival (Table 4). In addition, the multivariate regres-
sion showed that tumor depth invasion was also an inde-
pendent correlate (hazard ratio, 2.44; P  .045).
Factors Associated With Survival in Patients With
cM1a Disease
In an effort to identify factors associated with improved
survival in the patients with EUS-identified celiac adenop-
athy (cM1a), a separate analysis was performed on this
subset of patients. Univariable Cox regression (Table 5)
showed that the only factor associated with improved sur-
vival in this high-risk subset was the addition of induction
chemotherapy before concurrent chemoradiotherapy in the
preoperative regimen (Figure 2).
Discussion
Controversy continues to exist regarding the current treat-
ment and prognosis of patients with celiac axis adenopathy.
Most studies have suggested that celiac adenopathy is a
poor prognostic factor, especially when treated with surgi-
cal intervention alone.1,3,6,7 In this study we attempted to
evaluate a more homogeneous subpopulation of patients by
limiting our study to patients who had undergone pretreat-
ment EUS and had nonmetastatic adenocarcinoma of the
tified node status
N1 M0 (n  97) cM1a (n  18) P value
.30
72 (74%) 10 (56%)
14 (15%) 5 (28%)
11 (11%) 3 (17%)
0 (0%) 0 (0%)
1 (1%) 0 (0%) .22
25 (26%) 3 (17%) .65
.55
29 (29%) 3 (16%)
17 (18%) 4 (22%)
13 (13%) 1 (6%)
39 (40%) 9 (50%)
0 (0%) 1 (6%)
31 (32%) 9 (50%) .29
3 (3%) 5 (28%) .001
5 (5%) 1 (6%) .53
25 (26%) 8 (44%) .07
.03*
38 12
51% 14%
.03*
45 19
56% 12%
(cN0 M0 and cN1 M0) versus the cM1a group. †Median potential follow-upiden
c
roup distal esophagus or gastroesophageal junction. In an attempt
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subset, only patients who were treated with preoperative
chemoradiation and underwent an esophageal resection
were included.
The identification of celiac lymph nodes by means of
ultrasonography has been found in experienced hands to be
quite predictive of pathologic involvement. Results from 2
series demonstrate a sensitivity and specificity with EUS
alone of 67% to 77% and 85% to 87%, respectively.8,9
Catalano and colleagues10 found that preoperative detection
TABLE 3. Univariate Cox regression analysis of pretreat-
ment risk factors for long-term survival in patients with
adenocarcinoma of the distal esophagus
Risk factor HR CI P value
Patient age 1.01 0.98-1.03 .63
Sex
Male 1
Female 0.71 0.23-2.29 .57
Histologic grade .46
Well differentiated 1
Moderately differentiated 2.33 0.55-9.91 .25
Poorly differentiated 2.49 0.59-10.5 .21
T stage (EUS identified)
cT1/T2 1
cT3/T4 1.62 0.77-3.40 .20
Tumor size (EGD identified)
5 cm 1
5 cm 1.13 0.69-1.86 .64
Barret’s mucosa*
No 1
Yes 1.55 0.95-2.52 .08
N stage (EUS identified)
cN0 1
cN1 1.18 0.71-1.97 .51
Node size (EUS identified)
1.0 cm 1
1.0 cm 1.24 0.64-2.39 .52
M stage (EUS identified)
cM0 1
cM1a 2.01 1.06-4.13 .04
ASA class† .05
2 1
3 1.39 0.74-2.62 .30
4 4.08 1.30-12.85 .02
Preoperative therapy
C/RT 1
C¡C/RT 0.73 0.44-1.22 .23
HR, Hazard ratio; CI, confidence interval; EUS, endoscopic ultrasonogra-
phy; EGD, esophagogastroduodenoscopy; C/RT, concurrent chemoradio-
therapy; C¡C/RT, induction chemotherapy followed by concurrent
chemoradiotherapy. *Barrett’s mucosa was determined by means of pre-
treatment EGD and biopsy. †Performance status defined by the American
Society of Anesthesiologists (ASA).of celiac lymph nodes by means of EUS with characteriza-
The Journal of Thoraction by size, shape, echogenicity, and borders had a sensi-
tivity and specificity of 83% and 98%, respectively, for
involvement. False-positive results occurred in only 2 of
145 patients. This has led Eloubeidi and associates8 to
hypothesize that the mere detection of celiac axis lymph
nodes was highly predictive of malignant involvement. Fur-
thermore, celiac lymph nodes larger than 10 mm have been
shown in some studies to be histologically involved 100%
of the time.3 In our study celiac adenopathy was not diag-
nosed pathologically before treatment, and the use of neo-
adjuvant therapy precluded postoperative confirmation. De-
spite this potential inaccuracy, the detection of celiac
adenopathy on a pretreatment EUS in our study was a strong
and independent negative prognostic indicator. Unlike
EUS-identified adenopathy in other lymph node locations,
such as the mediastinum or paraesophageal region (cN1),
celiac adenopathy (cM1a) was a strong predictor of poor
outcome, even after preoperative chemoradiation. This is not
completely unexpected because previous reports by our group
have demonstrated that almost all pretreatment tumor charac-
teristics lose validity after preoperative chemoradiation, with
pathologic response and posttreatment pathologic stage be-
coming the most important predictors of survival.11,12 This
study suggests that EUS-identified pretreatment celiac ade-
nopathy is such a powerful prognostic factor that even after
preoperative chemoradiation, it maintains a negative predic-
tive value.
The reason that celiac adenopathy portends such a poor
prognosis might be the systemic nature associated with
involvement of the celiac axis. The 2001 American Joint
TABLE 4. Multivariate Cox regression analysis of pretreat-
ment risk factors for long-term survival in patients with
adenocarcinoma of the distal esophagus
Risk factor HR CI P value
T stage (EUS identified)
cT1/T2 1
cT3/T4 2.44 1.02-5.83 .045
M stage (EUS identified)
cM0 1
cM1a 2.18 1.20-4.32 .03
Barrett’s mucosa*
No 1
Yes 1.64 0.99-2.70 .055
ASA class† .02
2 1
3 1.43 0.76-2.69 .26
4 4.32 1.37-13.65 .01
HR, Hazard ratio; CI, confidence interval; EUS, endoscopic ultrasonography.
*Barrett’s mucosa determined by means of pretreatment esophago-
gastroduodenoscopy. †Performance status defined by the American So-
ciety of Anesthesiologists (ASA).Committee on Cancer13 classifies celiac axis involvement as
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because of the high likelihood of relapse when surgical
intervention alone is used. Steup and coworkers14 reported
a 5-year survival of 15% in patients with gastroesophageal
cancer and distant lymph node metastasis (including tho-
racic and celiac lymph node metastasis). More recently,
Eloubeidi and associates3 have also demonstrated poor sur-
vival in patients with specifically celiac lymph node metas-
tasis when surgical intervention alone is used, with 5-year
survivals of 13% compared with 30%. Although our study
was limited by the small number of patients with EUS-
identified celiac adenopathy, there appeared to be a ten-
dency toward a higher proportion of patients who relapsed
systemically as opposed to locoregionally (Table 2). Sys-
temic relapse for patients with cM1a disease was 44%
versus 18% and 26% for patients with cN0 M0 and cN1 M0
disease (P  .07). Interestingly, locoregional relapse was
similar between the groups, suggesting that additional im-
provements in survival for patients with cM1a disease might
TABLE 5. Univariate Cox regression analysis of pretreat-
ment risk factors for long-term survival in patients with
cM1a disease
Risk factor HR CI P value
Patient age 1.02 0.96-1.08 .46
Sex
Male 1
Female 0.79 0.09-6.32 .79
Histologic grade
Moderately differentiated 1
Poorly differentiated 1.43 0.40-5.13 .58
T stage (EUS identified)
cT1/T2 1
cT3/T4 0.45 0.09-2.31 .40
Tumor size (EGD identified)
5 cm 1
5 cm 3.61 0.75-17.43 .11
Barrett’s mucosa*
No 1
Yes 0.97 0.18-5.28 .97
ASA class† .15
2 1
3 1.54 0.31-7.57 .60
4 20.13 0.95-425 .05
Preoperative therapy
C/RT 1
C¡C/RT 0.19 0.04-0.97 .04
HR, Hazard ratio; CI, confidence interval; EUS, endoscopic ultrasonography;
EGD, esophagogastroduodenoscopy; C/RT, concurrent chemoradiotherapy;
C¡C/RT, induction chemotherapy followed by concurrent chemoradiotherapy.
*Barrett’s mucosa was determined by means of pretreatment EGD and
biopsy. †Performance status identified by the American Society of Anes-
thesiologists (ASA) criteria.need to focus on better systemic control.
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adenopathy is associated with a poor prognosis, the pres-
ence of long-term survivors is encouraging. Other studies
have confirmed that there are long-term survivors with
celiac lymph node disease, and the application of aggressive
multimodal therapy, including surgical resection, might be
warranted.15 In an attempt to identify the subset of patients
with cM1a disease who might benefit from preoperative
chemoradiation and surgical intervention, multiple factors
were analyzed univariably, including age, sex, histologic
grade, tumor and nodal size, performance status, and type of
preoperative chemoradiation used. Although the small num-
bers prevent meaningful multivariable analysis, univariable
analysis demonstrated improved survival in the group of
patients who received additional chemotherapy before con-
current chemoradiation, perhaps because of improved sys-
temic treatment. The addition of induction chemotherapy
before concurrent chemoradiotherapy has been shown to
improve overall response rates of locally advanced esoph-
ageal tumors in several phase II trials,16-18 and it is possible
that this intensive regimen is beneficial to patients with
celiac axis disease. The poor prognosis of this group of
patients warrants further evaluation of the role of induction
chemotherapy before concurrent chemoradiation in a pro-
spective fashion. Additionally, novel biologic agents might
need to be investigated to seek long-term improvement in
this difficult group of patients.
It is important to emphasize the limitations inherent in
this retrospective study, including the fact that only patients
who completed preoperative chemoradiation and surgical
intervention were included, leading to bias for higher per-
Figure 2. Overall survival of patients with pretreatment, EUS-
identified cM1a disease according to preoperative chemoradio-
therapy sequence. C/RT, Concurrent chemoradiotherapy; C¡C/RT,
induction chemotherapy followed by concurrent chemoradiother-
apy (P  .02).formance status patients. Although the results of 2 phase II
ry 2006
Malaisrie et al General Thoracic Surgery
G
TStrials16,17 at our institution showed that 91% of patients
receive their planned dose of chemoradiation, the total per-
centage in the current study group is unknown because
many patients received their preoperative treatment at an-
other institution. Additionally, the small number of patients
in the cM1a study group limits the conclusions that can be
reached because many factors showed a trend toward being
predictors of survival but failed to reach statistical signifi-
cance. The nonrandomized nature of the study might also
have led to selection bias because only patients with higher
performance status might have been offered additional in-
duction chemotherapy before concurrent chemoradiation,
and finally, the lack of histologic confirmation of celiac
lymph node metastasis before the institution of treatment
limits our ability to reach definitive conclusions regarding
pathologic involvement of the celiac axis.
Despite these limitations, our study confirms and extends
previous observations that EUS-identified celiac adenopa-
thy is a poor prognostic factor, even when treated with
preoperative concurrent chemoradiation. Identification of
this high-risk group before treatment might warrant the
inclusion of these patients in novel treatment strategies.
Pathologic confirmations of celiac lymph node metastasis
by means of EUS–fine-needle aspiration should be included
in future studies involving preoperative therapy. Prospective
trials might be warranted to evaluate the benefit of aggressive
preoperative regimens aimed at improved systemic control for
this high-risk group of patients.
We thank Alma Vega and Debbie Smith for help in preparation
and review of the manuscript.
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Discussion
Dr Carolyn E. Reed (Charleston, SC). This study confirms what
our group at the Medical University of South Carolina and the
Cleveland Clinic have previously shown: M1a disease is a marker
of poor clinical outcome. The authors have extended this obser-
vation and documented that patients with adenocarcinoma of the
distal esophagus and M1a disease identified by means of endo-
scopic ultrasonography (EUS) have poor outcome, even after
aggressive induction therapy.
This article has several limitations. It is retrospective and
nonrandomized; the number of patients is small, 18 patients;
induction therapy varied; and, most importantly, metastatic celiac
nodes were not validated by means of EUS–fine-needle aspiration
(FNA). Only 5 of 18 patients had metastatic celiac nodes at the
time of surgical intervention. Considering the overall pathologic
complete response rate of 26%, it is unlikely that 70% of patients
with M1a disease were downstaged to M0. The authors suggest
that patients with clinical M1a disease could benefit from induc-
tion chemotherapy, followed by concurrent chemoradiotherapy.
This might be a reasonable multicenter approach, but histologic
confirmation with EUS-FNA should be required.
I have several questions for the authors. One, why did you not
use EUS-FNA? We really do not know how many patients truly
had M1a disease.
Dr Malaisrie. We only started using routine EUS-FNA re-
cently, and indeed, 5 of the 18 patients with cM1a disease did
undergo FNA before treatment. Because of that small number, we
excluded FNA documentation from the analysis, yet despite the
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alone were still a strong negative independent predictor of poor
outcome.
Dr Reed. Second, if you used EUS-FNA in your next study,
and celiac lymph nodes were still positive after induction therapy,
would your group still recommend surgical intervention?
Dr Malaisrie. I think the short answer to that is, yes, they
would get treated. This is mainly because most of our patients are
treated on protocol, and unless distant disease is present, surgical
resection is still performed. If multicenter studies can be performed
in the future, perhaps data will one day exist to know how to
proceed with this difficult group of patients.
Dr Reed. Three-year survival was the same for clinical N0 M0
and clinical N1 M0 disease. How do you explain this? How did
EUS clinical N1 disease correlate with pathologic N1 disease?
Dr Malaisrie. The reason patients with cN1 M0 and cN0 M0
disease had similar survival might be due in part to the fact that the
clinical staging was obtained before pathologic downstaging by
preoperative chemoradiation. If patients are simply treated with
surgical intervention alone without preoperative chemoradiation,
patients with EUS-identified cN0 M0 disease do much better than
those with cN1 M0 disease. Despite preoperative chemoradiation,
however, patients with cN1 M1a disease do much worse, and I
think this is the take-home message: this is a worse group of
patients, perhaps with more micrometastatic disease that does not
respond well to standard preoperative chemoradiation.
Dr Reed. Finally, did those patients with clinical N1 disease
receiving induction chemotherapy followed by chemoradiother-
apy, your 3-stage approach, versus chemoradiation also do better
clinically?
Dr Malaisrie. In this limited study there was a tendency toward
improved survival, but it did not reach statistical significance. In an
upcoming presentation at The Western Thoracic Surgical Associ-
ation meeting, we address this question in more detail in a larger
patient population.
Dr Reed. Thank you very much for a very well-presented
article.
Dr Mark J. Krasna (Baltimore, Md). To take a different tack
from Dr Reed’s question, there are a lot of data that were not
mentioned today talking about the outcomes of patients with
clinical M1a disease who just go to surgical intervention alone.
Presented here at this meeting several years ago by Dr Lerut’s
group in Belgium and by the group in New York by Rob Korst
were actually excellent outcomes of patients who had surgical
resection for adenocarcinomas of the gastroesophageal junction
and M1a lymph node with survivals that went anywhere from 17%
to as high as 30%. Therefore I do think we need to take a step back.
We do need to identify that there can be actually even better
survival in this subgroup of patients and that calling their disease
metastatic M1a disease was convenient for the staging system but
might in fact not be appropriate clinically.
My question, then, comes from a slightly different angle but
similar to what Dr Reed is alluding to. Can you identify these
patients up front pathologically with, as with Dr Reed and our
institution, EUS-FNA, or if we cannot find it by using the FNA, by
means of thoracoscopy or laparoscopy? You can then know the
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are 2 potential advantages to that. First, you can then allocate the
patients for the high-dose chemotherapy followed by the chemo-
radiotherapy protocol only as appropriate and not subject everyone
to the extra morbidity, which I know is significant. Second, you are
going to know your actual “n” in the denominator of your study;
you are going to know in whom there is some benefit.
Therefore the last question is, of those patients, and I do not
think you showed us these data, who did have clinical M1a disease
but had persistent M1a disease pathologically after the chemora-
diation, was there a difference? Our two prior articles from Mary-
land, phase I and phase II, looking at chemoradiotherapy followed
by surgical intervention, showed that the only important prognos-
ticator was persistent N1 disease, what you are calling M1a dis-
ease, after chemoradiotherapy. Was that in fact looked at? It was
not listed on your list of variables.
Dr Malaisrie. Thank you, Dr Krasna.
We did look at those data, but because of the small number of
patients, we cannot give a definitive answer.
In the 18 patients who we identified with cM1a disease by
means of EUS, at the time of surgical intervention, 4 patients had
pathologic M1a disease. Of those 4 patients, 2 are dead at current
follow-up. They died at 10 months and 26 months, respectively.
The 2 who are alive are still alive at 15 and 18 months.
Dr Krasna. Was that included as one of your variables in the
multivariate analysis, response rate? It might turn out to be at least
as important as the trimodality versus bimodality approach.
Dr Malaisrie. Perhaps it will be a significant factor, but this
will require more patients to confirm.
Dr Stephen D. Cassivi (Rochester, Minn). Thanks. I was very
interested in your presentation, and I have a comment that perhaps
evolves into a question.
First of all, thank you for bringing another article that under-
lines the importance of proper staging in esophageal cancer. How-
ever, I would underline what Dr Reed and Dr Krasna were men-
tioning. Specifically, unless you have the FNA, I am not sure we
actually know what the true status of those lymph nodes was. You
talked about a 30% false-positive rate in the N1 nodes alone. I
think that is brought out by the fact that your median survivals for
your patients with N1 and N0 disease are virtually the same at
around 48 months.
What criteria were you using by EUS if you were not using
FNA to determine which nodes were positive?
Dr Malaisrie. The 4 criteria that were used by our group were
size greater than 1 cm, sharp borders, less echogenicity than the
surrounding tissues, and round shape. Our endoscopists consis-
tently used at least one of these criteria to define patients with
cM1a disease.
I would like to point out again that this article does give some
prognostic information, but I want to be very careful about giving
any sort of treatment recommendations because of the small num-
bers. Our article demonstrates that EUS-identified celiac adenop-
athy identifies a poor prognostic group that is difficult to care for,
even with preoperative chemoradiation. Whether the use of FNA
will help to further refine this group in the future remains to be
determined by future prospective multicenter studies.
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